Risk for cardiovascular events in an Italian population of patients with type 2 diabetes
Section snippets
Study population and data collection
We analysed 15,000 clinical charts of diabetic patients followed by the three Diabetes Clinics of Modena.
The study was retrospective, composed of a phase of ‘enrolment’ embracing the period between January 1991 and December 1995, and a longitudinal phase of ‘follow-up’ of 10 years.
In order to compare the different algorithms examined, we homogenised the criteria of enrolment to include Caucasian patients with type 2 diabetes mellitus of both sexes, in the age range of 35–65, with a duration of
Results
Starting from the analyses of 15,000 clinical charts, we selected in our database 4562 type 2 diabetes patients with a visit between January 1991 and December 1995.
A total of 1532 patients, 934 men (61%) and 598 women (39%), fulfilling inclusion criteria and with complete data were suitable for the study; statistic analysis deriving from the algorithms of the different studies (the UKPDS, Framingham, Riskard and Progetto Cuore) was applied.
The characteristics of these two groups are described
Discussion
CVD is the major cause of morbidity and mortality in industrialised countries. Diabetes represents an important risk factor, when we consider that diabetic patients present a two- to fourfold incidence of CVD, compared to age- and sex-matched non-diabetic persons [3], [12]. In the elderly, the prevalence of diabetes increases and its impact on cardiovascular risk is particularly evident [18], [19].
Different randomised studies have described beneficial effects of an intensive intervention on a
Acknowledgements
This work was partly supported by a grant from the Regione Emilia Romagna within the Programma di Ricerca Regione-Università 2007–09 – Research for Clinical Governance.
References (35)
- et al.
Changes over time in the prevalence and quality of care of type 2 diabetes in Italy: the Casale Monferrato surveys, 1988 and 2000
Nutr Metab Cardiovasc Dis
(2008) - et al.
Socio-economic differences in the prevalence of diabetes in Italy: the population-based Turin study
Nutr Metab Cardiovasc Dis
(2008) - et al.
Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year follow-up in a Mediterranean population
Nutr Metab Cardiovasc Dis
(2009) - et al.
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
J Am Coll Cardiol
(2008) - et al.
Should we screen for occult coronary artery disease among asymptomatic patients with diabetes?
J Am Coll Cardiol
(2005) - et al.
Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular disease
Nutr Metab Cardiovasc Dis
(2005) - et al.
Vascular dysfunction and heart failure: epiphenomenon or etiologic agent?
Am Heart J
(2002) - et al.
Cardiovascular morbidity and mortality in COPD
Chest
(2005) - et al.
Principles for National and Regional guidelines on cardiovascular disease prevention. A scientific statement from the World Heart and Stroke Forum
Circulation
(2004) - et al.
Coronary heart disease incidence in northern and southern European populations: a reanalysis of the Seven Countries Study for a European coronary risk chart
Heart
(2000)
Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the multiple risk factor intervention trial
Arch Intern Med
Coronary risk prediction in adults (The Framingham Heart Study)
Am J Cardiol
Developing risk stratification charts for diabetic and non-diabetic subjects
Diabet Med
Effect of a multifactorial intervention on mortality in type 2 diabetes
N Engl J Med
Prediction of coronary heart disease using risk factor categories
Circulation
The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56)
Clin Sci
The risk functions incorporated in Riskard 2002: a software for the prediction of cardiovascular risk in the general population based on Italian data
Ital Heart J
Cited by (15)
Prognostic tools for cardiovascular disease in patients with type 2 diabetes: A systematic review and meta-analysis of C-statistics
2019, Journal of Diabetes and its ComplicationsReclassification of cardiovascular risk by myocardial perfusion imaging in diabetic patients with abnormal resting electrocardiogram
2014, Nutrition, Metabolism and Cardiovascular DiseasesComparative performance of diabetes-specific and general population-based cardiovascular risk assessment models in people with diabetes mellitus
2013, Diabetes and MetabolismCitation Excerpt :The DCS risk models were better than the New Zealand adaptation of the Framingham model, as well as the original Framingham equation [24]. The UKPDS risk score was better than the Progetto Cuore and the CHD-Riskard algorithms [32]. The difference in C-statistics was formally tested in two pair wise comparisons [24].
Conventional and unconventional cardiovascular risk factors in men with erectile dysfunction
2013, Journal of Sexual MedicineTwo Unconventional Risk Factors for Major Adverse Cardiovascular Events in Subjects with Sexual Dysfunction: Low Education and Reported Partner's Hypoactive Sexual Desire in Comparison with Conventional Risk Factors
2012, Journal of Sexual MedicineCitation Excerpt :The Progetto Cuore risk engine demonstrated a greater accuracy than other commonly used algorithms, such as the Framingham and PROCAM engines, in predicting the first major adverse CV event (MACE) in a population of Italian men [12]. Although Progetto Cuore risk score showed a good accuracy in detecting high‐risk subjects, it has also demonstrated to underestimate CV risk in specific patient populations, such as those with diabetes, heart failure, or chronic obstructive pulmonary disease [13]. This is not surprising as the Progetto Cuore engine developed in the general population does not include risk factors that are specific for those affected by selected diseases, e.g., microalbuminuria in diabetes and brain natriuretic peptide in heart failure [13].